Advanced Biomed Inc. (ADVB) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, ADVB carries an RQD Score of 32 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 4 / 20 (ROIC -9.1%; FCF yield 0%), signaling that the business is not currently generating returns on invested capital or free cash flow. Whale 13F Flow scores 3 / 20 for institutional accumulation and options positioning, the weakest pillar in the set. Insider Conviction scores 5 / 20 on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10 / 20 with a Beta of 1.0 and noted sector sensitivity. Forensic Balance Sheet scores 10 / 20, reflecting an Altman Z of 2.5, a Piotroski F of 1/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to a profile in which the primary upside drivers are not visible in the cash-generation, ownership-flow, or insider-conviction pillars. The valuation tradeoff is stark: the market capitalization of $4.4M sits against reported net losses in both periods, with no positive margin or earnings metric available to anchor a valuation. The Piotroski reading of 1/9 indicates weak scoring across the nine fundamental tests, and the RQD framework treats this combination as forensic risk. The analytical takeaway is that the rating frames ADVB as a name where downside risk dominates the evidence in the source data.

Advanced Biomed Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical Specialities industry, per the Profile section. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in both FY 2025 and FY 2024 per the SEC financials, so the source data provides no evidence of how the company currently monetizes its operations.

Per the SEC financials, both reported periods show zero revenue and net losses, with FY 2025 net loss of $-3.3M and FCF of $-5.9M. Gross, operating, and net margins are each recorded as 0% in the market data. ROIC is -9.1%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity of 0.5. Cash and debt balances are not available in source data.

The news wire contains six items dated within the prior 15 hours of the data timestamp, all tagged to ADVB and carrying a YELLOW light and MARKET WIRE impact label. Headlines reference an options chain page (Moomoo), an estimates page (TradingView), a seasonal returns chart (Yahoo! Finance Canada), a penny-stock report noting an 11% rise on a Wednesday that remains far below its August high following an AI pivot (kalkine.ca), a gap-up and gap-down session listing for October 16, 2026 (ChartMill), and a health care intraday movers roundup (Benzinga). The AI pivot referenced in the kalkine.ca headline is the only described strategic development in the wire. Risk watch items include the -11.41% price change and the stock trading near the low end of its 52-week range. The Butterfly supply-chain graph reports no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Sector and industry are Health Care and Medical Specialities. The source data does not identify upstream suppliers, downstream customers, or correlated peers, so no 2nd-order ripple effects can be mapped from the provided material. An investor should note that the absence of supply-chain links means the graph cannot corroborate or contradict the RQD pillar readings.

• What products or services generate the company's operations given zero reported revenue in both periods?
• What are the cash and debt balances, and how long does the company's cash position sustain the reported FCF burn?
• What is the nature and timing of the AI pivot referenced in the news wire, and what capital requirements does it carry?
• Why did the share price fall from a 52-week high of $24.23 to a low of $2.25, and what events drove that decline?
• What are the terms and dilution implications of any financing needed to fund continued losses?